When antibiotics are not enough: the case for immune-engaging therapies

shutterstock_2748250717

As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.

Antibacterial drug discovery has traditionally focused on identifying compounds that inhibit or kill pathogens. However, clinical outcomes depend on more than bacterial susceptibility alone. The immune system plays a critical role in clearing infection and when that response is impaired, even effective antibiotics can fall short. In response, approaches that combine direct antibacterial activity with immune engagement are being developed to address both pathogen burden and host response. Dr Helen Bright, Chief Scientific Officer at Centauri Therapeutics, is working in this area, focusing on the Alphamer® platform, which recruits naturally occurring antibodies.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

  • Unlimited access to industry intelligence that can make a difference to your business
  • A weekly newsletter keeping the most vital information at the front of your thinking
  • Exclusive invitations to powerful webinars and events featuring high profile experts
  • Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member